Drug intelligence / Profile preview

GENEVAX IL-12

Development stage: Unknown
Lead developer: Aurobindo Pharma
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

GENEVAX IL-12 is a DNA vaccine developed by Drexel University. It acts as an immunostimulant, targeting immune system diseases, infectious diseases, and urogenital diseases. The drug is designed to stimulate the immune system, potentially enhancing responses against infections or diseases.

Brand names: GENEVAX IL-12 DNAGENEVAX IL-12-4532
Other names: HSV-2 therapeutic vaccine (Auro Vaccines)Herpes simplex virus type 2 DNA plasmid vaccineHSV-2 therapeutic DNA vaccineHSV2 therapeutic DNA vaccineHSV 2 therapeutic DNA vaccine

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on GENEVAX IL-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENEVAX IL-12.

Explore the full profile